FDA/CMS Info Sharing Could Lead To Quicker Reimbursement Decisions, McClellan Says
This article was originally published in The Pink Sheet Daily
Executive Summary
CMS Administrator McClellan cites drug-eluting stents as an example of a new technology that received reimbursement immediately following product approval as a result of cooperation between the two agencies.
You may also be interested in...
FDA/CMS Formal Collaboration Will Include Data Sharing, Parallel Review
A draft memorandum of understanding is under review at both agencies, Centers for Medicare & Medicaid Services Chief Medical Officer Sean Tunis, MD, told the BIO annual meeting in San Francisco. The MOU will address parallel review for new technologies, and allow the agencies to share scientific expertise and data.
FDA/CMS Formal Collaboration Will Include Data Sharing, Parallel Review
A draft memorandum of understanding is under review at both agencies, Centers for Medicare & Medicaid Services Chief Medical Officer Sean Tunis, MD, told the BIO annual meeting in San Francisco. The MOU will address parallel review for new technologies, and allow the agencies to share scientific expertise and data.
McClellan To Head Medicare Rx Law Implementation: Will Greater FDA/CMS Cooperation Ensue?
President Bush nominates FDA Commissioner McClellan to head Centers for Medicare & Medicaid Services Feb. 20. McClellan's closest advisors will remain at FDA, suggesting era of greater cooperation between the two agencies could result.